TOP TEN perturbations for NM_000171 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000171
Selected probe(set): 207972_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000171 (207972_at) across 5339 perturbations tested by GENEVESTIGATOR:

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.9482837
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ? 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.9345846
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ? 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.92183924
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ? 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):0.8667145
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

glioma study 17 (oligodendroglioma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.86141443
Number of Samples:3 / 3
Experimental glioma study 17 (oligodendroglioma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade oligodendroglioma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 39 ? 9 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Langerhans cell histiocytosis study 2 (multifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):0.8549843
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.8526888
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.8190651
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ? 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):0.71592236
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton?s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton?s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Langerhans cell histiocytosis study 2 (multifocal) / Langerhans cell histiocytosis study 2 (unifocal)

Relative Expression (log2-ratio):0.7072849
Number of Samples:2 / 8
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).